RxDoctor Payments Data

Henny Billett, MD

Hematology · Bronx, NYNPI 1689755001

Payments from drug & device makers

What this record shows

This record is dominated by education: $1,155 of the $1,187 with a category attached, or 97.2%. New York Blood Center, Inc. accounts for 97.2% of it on its own, with 2 other manufacturers making up the rest. 2025 is the largest year on record at $1,155, more than ten times the $20 reported in 2019. That places this record below the midpoint for hematology clinicians in NY, where the typical reported total is $619.

$1,187in general payments, 2019–2025

Across 3 payments — averaging $395.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • New York Blood Center, Inc.$1K
  • Novartis$20
  • Takeda Pharmaceuticals U.S.A., Inc.$13
$294,345in research payments, 2019–2025

Across 25 payments — averaging $11,774 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Global Blood Therapeutics, Inc.$271K
  • Novartis$18K
  • Janssen Research & Development, LLC$6K

What the payments were for

  • Food & beverage$333%
  • Education$1,15597%

General payments by program year

19
20
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
New York Blood Center, Inc.1$1,155
Novartis1$20
Takeda Pharmaceuticals U.S.A., Inc.1$13

How this compares

$1,187 in reported general payments places this provider in the 50th percentile of 157 hematology providers in New York.

See all hematology providers in New York

Medicare billing

Part B allowed, 2024
$17,642
Medicare patients
132
Services billed
216

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban32$40,219
Tranexamic Acid13$1,194
Warfarin Sodium21$74

Paid to pharmacies, not to this prescriber.

Other hematology in Bronx

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →